The rise of copyright’s blockbuster initially sparked a period of growth for pharma, however recent shifts present a complicated outlook for shareholders. Lower-cost versions are eroding earnings, and continued patent challenges add additional risk to the situation. While certain companies might still benefit from adjacent products, the general d